A Phase 1/2 interventional study of 2 mL SunButyrate-TG and Placebo in Congenital Heart Disease (CHD), sponsored by University of Nebraska. Recruiting at 1 site in United States. Open to participants aged 1 Month to 3 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by University of Nebraska · Phase 1/2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 356 studies in Heart Defects, Congenital with a site in United States — 67 open to participants now, 87 under way, 4 of them phase 3. Heart Defects, Congenital · United States.
Among the 356 studies in Heart Defects, Congenital with a site in United States, this one is the 48th largest by planned enrollment of the 184 interventional ones that give a count, is one of 15 that started in 2026, is one of 8 in phase 1/2, reaches primary completion later than 71 of the 86 other live ones, and was the 336th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →67 of the 356 studies in Heart Defects, Congenital with a site in United States are open now. Recruiting first, the newest first:
Le Bonheur Children's Hospital · Sites in United States
Ages 0 mo–12 mo
Carelon Research · Sites in United States
Ages 18+
Carelon Research · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
Starlight Cardiovascular Inc · Sites in United States
Ages 1 min–6 mo
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 1 Month to 3 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
356 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 33 · Phase 3 25 · Phase 4 9
First in 1980; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 105 is above the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 48 across the 184 interventional studies, 72 across the 167 observational. Of the 241 that completed or were terminated, 62 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 356 have an industry lead sponsor. The 10 most frequent:
University of Nebraska is the lead sponsor of 496 studies on the registry; 66 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 53 (64%) have results posted.
University of Nebraska has 1 study filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
29 of the studies in Heart Defects, Congenital with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04216927Phase 3Children's Hospital Medical Center, CincinnatiNO During CPB in Neonates to Reduce Risk of AKI | 2027-06-30 |
| NCT05077774Medtronic CardiovascularHarmony TPV Post-Approval Study | 2026-11 |
| NCT07559253University of Wisconsin, MadisonImplementation of an Accessible Healthcare Model (ACHD STRONG): Comparing Nurse and Physician Lead Healthcare Transition Education in a RE-AIM Framework | 2026-11-30 |
| NCT04236479Catherine BollardMesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP) | 2026-12 |
| NCT05849025Mayo ClinicA Study of Invasive Hemodynamic for MACHD Registry | 2026-12 |
Add all 29 to your calendar (.ics) → With an account.
Among the 356 studies in Heart Defects, Congenital with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Butyric acid has been shown to promote gut health and improve the microbiome in multiple adult studies. In preliminary studies in older children with inflammatory bowel disease, butyric acid was shown to be safe. However, it's suitability for infants and young children with congenital heart disease (CHD) has yet to be determined.
This study will examine butyric acid supplementation in infants and children, ages 1 month to 3 years, with CHD who require cardiac surgery with cardiopulmonary bypass. Study goals include determining the safety and tolerability of butyric acid supplementation before cardiac surgery, and to identify changes in gut microbial communities, metabolic profile, and genetic markers intestinal function. Also, the study seeks to establish a reduction in inflammation (inflammatory signaling) after cardiopulmonary bypass (CPB) in participants receiving butyric acid.
The goal of this study is to supplement a liquid form of butyric acid once daily for 3 weeks prior to cardiac surgery for infants and children, ages 1 month to 3 years, with congenital heart disease to improve their pre-operative gut microbiome in efforts to reduce post-operative gut permeability and reduce post-operative inflammatory signaling.
Up to 35 participants will be enrolled in each of three arms:
Participants will be asked to:
Study aims:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive 2 milliliter (mL) SunButyrate-TG once daily for 3 weeks prior to cardiac surgery.
Drug: 2 mL SunButyrate-TG
Participants will receive 4 milliliter (mL) SunButyrate-TG once daily for 3 weeks prior to cardiac surgery.
Drug: 4 mL SunButyrate-TG
Participants will receive either 2 milliliter (mL) or 4 mL of an inactive oil-based placebo once daily for 3 weeks prior to cardiac surgery.
Drug: Placebo
Participants randomized into the 2 milliliter (mL) SunButyrate-TG will take the supplement once daily for 3 weeks prior to cardiac surgery. Note: This is a Dietary Supplement, but the FDA requires an Investigational New Drug (IND) number because inflammation is being treated.
Also known as: Butyrate Liquid Supplement
Participants randomized into the Placebo arm will take the oil-based placebo once daily for 3 weeks prior to cardiac surgery
Also known as: sugar pill
Participants randomized into the 4 mL SunButyrate-TG arm will take the supplement once daily for 3 weeks prior to cardiac surgery. Note: This is a Dietary Supplement, but the FDA requires an Investigational New Drug (IND) number because inflammation is being treated.
Also known as: Butyrate Liquid Supplement
Combined Incidence of Adverse Events and Serious Adverse Events with Butyric Acid (SunButyrate-TG) Supplementation
Safety will be measured by the combined incidence of adverse events (AE) and serious adverse events (SAE). These include allergic reaction, vomiting, diarrhea, abdominal distention, infection, hospitalization, or any other concern the families report. A Data Safety Monitoring Board (DSMB) will review and catalog the incidence and severity to determine study continuation. Investigators will evaluate each AE/SAE to determine the safety of the supplement in this age and participant population. AE and SAE definitions used according to FDA regulations. A scoring system of 1-5 will be used to determine the severity of the AE after review by the DSMB. A cumulative score of 3 or greater will require cessation of the study for that individual. If an accumulation of 20 participants or more have a score \>3 the study will be stopped. If an accumulation of SAE (score of 5) in 8 or more participants, the study will be stopped.
Time frame: 3 years
Tolerance of SunButyrate-TG
Tolerance will be measured by the incidence of nausea, inability to consume the supplement, or parental concern of intolerance. The tolerance scoring metric will be used to aggregate the listed criteria into a score for each participant. Each characteristic will receive a point. If a participant has a score of 2 or greater, it will be defined as intolerance. Participant study continuation will be discussed with the family in weekly calls during the supplementation period.
Time frame: Baseline to 3 weeks
Changes to White Blood Cell Count with SunButyrate-TG Supplementation
Safety will be evaluated through measurement of the white blood cell (WBC) count of the complete blood cell (CBC) count. Investigators will evaluate changes between the pre- and post-supplementation period CBC looking at changes in WBC count to quantify the incidence of leukocytosis (WBC \> 15.0 x 10\^9/L) and leukopenia (WBC \< 6.0 x 10\^9/L) after completing the supplement and prior to the surgery. Any participant that has a WBC count higher or lower than the values stated above will be documented.
Time frame: Baseline to 3 weeks
Changes to Hematocrit with SunButyrate-TG
Investigators will measure hematocrit between pre- and post-supplement time points to determine the effect of SunButyrate-TG. Investigators will evaluate changes between the pre- and post-supplementation period complete blood count (CBC) looking at changes in of anemia (hematocrit \< 29%) or polycythemia (hematocrit \> 45%) after completing the supplement and prior to the surgery. Any participant that has a hematocrit higher or lower than the values stated above will be documented.
Time frame: Baseline to 3 weeks
Changes in Platelets with SunButyrate-TG
Safety will be evaluated through measurement of the white blood cell (WBC) count of the complete blood cell (CBC) count. Investigators will evaluate changes between the pre- and post-supplementation period complete blood count looking at changes in platelet (PLT) count to quantify the incidence of thrombocytopenia (PLT \< 30 x 10\^9/L) or thrombocythemia (PLT \> 750 x 10\^9/L). Any participant that has a PLT count higher or lower than the values stated above will be documented.
Time frame: Baseline to 3 weeks
Changes to Renal Function (BUN, Creatinine or urine output) with SunButyrate-TG
Investigators will collect blood for a comprehensive metabolic panel before and after supplementation with SunButyrate-TG. Investigators will evaluate the changes in blood urea nitrogen (BUN) and Creatinine to determine evidence of renal impairment or acute kidney injury based upon Kidney Disease: Improving Global Outcomes (KDIGO) criteria (creatinine increase 1.5-1.9 times baseline or \>0.3 mg/dL increase), or urine output \< 0.5 mL/kg/h for 6-12 hours (excluding overnight for potty-trained children).
Time frame: Baseline to 4 months
Changes in Liver Function with SunButyrate-TG
Investigators will collect blood and measure a comprehensive metabolic panel before and after supplementation for evidence of liver injury. Investigators will determine: 1. Presence of acidosis (pH\< 7.3) 2. Elevation of transaminitis (AST/ALT \> 3 x baseline) 3. Elevation in INR (\>2 if not on coumadin) 4. Elevation in Bilirubin (\>2 mg/dL) 5. Elevation in alkaline phosphatase (\> 2 x baseline) If a participant meets any one of the above criteria, this will be considered evidence of liver injury and reported.
Time frame: Baseline to 4 months
Improvement in Gut Microbiome as Measured by Alpha Diversity, Shannon Diversity Index and Simpson Diversity Index with SunButyrate-TG Supplementation
Changes to the gut microbiome will be measured before and after supplementation, as well as post-operatively. Investigators will measure improvement in alpha diversity and the number of short-chain fatty acids (SCFA) producing bacterial populations. An improvement will be classified by an increase in alpha diversity of measurable OTU's by 12, Shannon diversity index (increase of 0.5), and Simpson diversity index (increase of 0.08), and specific number of SCFA producing organisms by 5 OTU's compared to the placebo group.
Time frame: Baseline to 4 months
Changes in Short-Chain Fatty Acids with SunButyrate-TG
Investigators will measure metabolite profiles to evaluate the amount of short-chain fatty acids (SCFA) in the gut and plasma before and after supplementation with SunButyrate-TG. This will be classified by a statistically significant increase (p\<0.05) in a list of 8 different SCFA. A positive increase in SCFA production will be classified by at least 1 SCFA being significantly increased following supplementation with SunButyrate-TG compared to the placebo group.
Time frame: Baseline to 4 months
Gut Barrier Function after SunButyrate-TG
Investigators will measure 3 plasma markers of intestinal barrier function between pre- and post-supplement, as well as post-operatively. These markers are claudin-2, claudin-3, and intestinal fatty acid binding protein (FABP2). An improvement in gut barrier will be considered if there is a statistically significant reduction in the plasma marker of any of these at the post-supplementation, or post-operative time points compared to the placebo group.
Time frame: Baseline to 4 months
Reduction of Post-Operative Cytokine Values
Investigators will measure cytokine levels pre- and post-surgery to determine changes in cytokine profiles of a panel of 8 different cytokines, including TNF-alpha, IL-1, IL-4, IL-6, IL-7, IL-8, IL-10, TGF-beta and IFN-gamma). An improvement in the cytokine profile will be considered if there is a statistically significant reduction in pro-inflammatory cytokines (IL-1, TNFa, IL-6, IL-4, or IL-8, IFN-gamma) or a significant increase in anti-inflammatory cytokines (IL-10 and TGF-beta) compared to the placebo group. These cytokines are measured together and will be considered a positive improvement in cytokine profiles if at least 2 pro-inflammatory cytokine values are reduced in conjunction with an increase in IL-10 and/or TGF-beta.
Time frame: Pre-surgery to 4 days post-operatively
Changes in Neutrophils After Surgery with SunButyrate-TG
Investigators will evaluate immune cell profiles in participants before and after surgery. Investigators will evaluate shifts in neutrophils. A significant change will be considered if there is a reduction of greater than 5% total neutrophil count via flow cytometry.
Time frame: Pre-surgery to 4 days post-operatively
Changes in Macrophages After Surgery with SunButyrate-TG
Investigators will evaluate immune cell profiles in participants before and after surgery. Investigators will evaluate shifts in macrophages. A significant change will be considered if there is a reduction of greater than 5% total macrophage count via flow cytometry.
Time frame: Pre-surgery to 4 days post-operatively
Changes in T-regulatory Cells After Surgery with SunButyrate-TG
Investigators will evaluate immune cell profiles in participants before and after surgery. Investigators will evaluate shifts in T-regulatory cells (T-cell). A significant change will be considered if there is an increase of greater than 10% in T-regulatory cell count via flow cytometry.
Time frame: Pre-surgery to 4 days post-operatively
Changes in Natural Killer T-cells Cells After Surgery with SunButyrate-TG
Investigators will evaluate immune cell profiles in participants before and after surgery. Investigators will evaluate shifts in natural killer T-cells (NK T-cell). A significant change will be considered if there is a reduction of greater than 10% total NK T-cell count via flow cytometry.
Time frame: Pre-surgery to 4 days post-operatively
Changes in Inflammatory Gene Activation
Investigators will measure inflammatory genes using an ribonucleic acid (RNA) hybridization panel and evaluate the level of activation of these genes pre-and post-surgery to determine a decrease in inflammatory signaling following supplementation with SunButyrate-TG compared to placebo. These inflammatory gene profiles are identified as a panel are are unable to be separated out. The entirety of the inflammatory gene profile will be evaluated together to assess changes in inflammatory gene activation.
Time frame: Pre-surgery to 4 days post-operatively
Plan to share: Yes — Participant information will be partially de-identified. Information related to age, gender, ethnicity, and cardiac lesion will be shared. Additional information regarding the cardiac surgery, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery (STAT) category, and lab values will also be included.
Supporting information: Study protocol, Clinical study report
Time frame: Information will be shared after completion of the study starting in 2029 and be available for 5 years.
Access criteria: Information will be shared upon request to the PI.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jun 2029, 31 months later.
Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Nov 2026, on Oct 30, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.